Merck KGaA to Buy Britain's Silence Therapeutics for $1.3 Billion in siRNA Push
Merck KGaA agreed to acquire Silence Therapeutics (SLN) for $1.3B in equity value, or $1.1B enterprise value. Deal values Silence at $20 per ADS, a 130% premium to Friday's close. Transaction expected to close in Q1 2027, subject to shareholder and regulatory approvals. Silence's board and 14% of shareholders support the deal. The acquisition focuses on divesiran, an siRNA candidate for polycythemia vera, which showed 88% response rates in phase 2 trials.
How this was made
The 30-second read
Why it matters
The acquisition creates a platform for Merck KGaA in rare‑blood cancers, potentially boosting its long‑term growth prospects while delivering immediate cash value to Silence shareholders.
Market read
The deal is a primary market‑moving event for both companies, with a sizable premium and immediate price impact on Silence's ADS.
What to watch
Closing timeline (Q1 2027) and required high‑court approvals introduce execution risk that may temper short‑term upside.
Background
Merck KGaA is expanding its rare‑disease pipeline through acquisitions, having recently bought Bio‑Techne and SpringWorks. Silence Therapeutics brings a late‑stage siRNA candidate for polycythemia vera.
Ticker impact
Silence Therapeutics announced it will be acquired by Merck KGaA for $20 per ADS, a 130% premium, driving its U.S.-listed shares up over 125% in pre‑market trading.
likely pressure as the market prices in the $20 per ADS acquisition price
The transaction is newly disclosed, premium is large, and the share price has already spiked; traders will focus on the deal completion risk and arbitrage to the cash price.
Market effects
Strengthens Merck KGaA's position in the rare‑disease siRNA space, may spur further M&A activity in biotech.
European biotech M&A momentum could lift related ADRs and European biotech ETFs.
Large‑scale biotech deal highlights continued investor appetite for rare‑disease therapeutics worldwide.
Counterpoint
If regulatory or clinical setbacks arise, the premium could be unjustified, leading to a sell‑off before closing.
Key entities
- CompanyMerck KGaA
German pharmaceutical group acquiring Silence Therapeutics.
- CompanySilence Therapeutics
British biotech developing siRNA therapies, target of the $1.3 B acquisition.
